Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan

<p>Abstract</p> <p>Background</p> <p>Limited data are available on the risk ratios for fatal cardiovascular disease (CVD) outcome from gout and chronic kidney disease (CKD) in non-diabetic individuals.</p> <p>Methods</p> <p>Nationwide population-...

Full description

Bibliographic Details
Main Authors: Kok Victor C, Horng Jorng-Tzong, Lin Hsin-Li, Chen Yu-Ching, Chen Yan-Jun, Cheng Kuang Fu
Format: Article
Language:English
Published: BMC 2012-11-01
Series:BMC Cardiovascular Disorders
Online Access:http://www.biomedcentral.com/1471-2261/12/108
id doaj-6c37a16e7b7e40d6be9e752d10e9c625
record_format Article
spelling doaj-6c37a16e7b7e40d6be9e752d10e9c6252020-11-25T03:40:10ZengBMCBMC Cardiovascular Disorders1471-22612012-11-0112110810.1186/1471-2261-12-108Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in TaiwanKok Victor CHorng Jorng-TzongLin Hsin-LiChen Yu-ChingChen Yan-JunCheng Kuang Fu<p>Abstract</p> <p>Background</p> <p>Limited data are available on the risk ratios for fatal cardiovascular disease (CVD) outcome from gout and chronic kidney disease (CKD) in non-diabetic individuals.</p> <p>Methods</p> <p>Nationwide population-based retrospective prospective study with a 5-year follow-up to investigate the association between physician-diagnosed gout and CKD in non-diabetics aged 50 and above who had no pre-existing serious CVD and the subsequent risk of death from CVD. Hazard ratios (HR) of CVD mortality were adjusted for gender, age, smoking- and alcoholism-related diagnoses, hypertension, hyperlipidemia, atrial fibrillation and Charlson’s comorbidity index score.</p> <p>Results</p> <p>A case cohort (n=164,463) having gout and a control cohort (n= 3,694,377) having no gout were formed. The prevalence of gout in this study was 4.26% whereas that of gout plus CKD was 8.17%. Male to female ratio among the individuals with gout was 3.2:1. The relative risk (RR) of subsequent cardiovascular mortality between the case and control cohort was 1.71 (95% confidence interval (CI), 1.66-1.75). The presence of CKD in nondiabetic subjects with no gout (control group) has a RR of CVD mortality at 3.05 (95% CI, 2.94-3.15). The presence of gout has protective effect on subjects with CKD with a RR of 1.84 (95% CI, 1.71-1.98). As compared with individuals with no gout, the adjusted HR (aHR) for CVD mortality among the individuals with gout was 1.10 (95% CI 1.07-1.13). In a Cox model, when compared with subjects having neither gout nor CKD, the aHR in subjects with no gout but with CKD is 1.76 (95% CI, 1.70-1.82); in subjects with gout but without CKD, 1.10 (1.07-1.13); interestingly, the aHR is attenuated in subjects with concomitant gout plus CKD which is 1.38 (1.29-1.48).</p> <p>Conclusions</p> <p>Among non-diabetic individuals aged 50 years or above who had no preceding serious CVD, those with gout were 1.1 times more likely to die from CVD as were individuals without gout. The presence of gout appears to attenuate the risk of subsequent CV mortality in subjects with CKD. Further studies should focus on finding an explanation for the protective effect of gout on CV mortality in patients with CKD.</p> http://www.biomedcentral.com/1471-2261/12/108
collection DOAJ
language English
format Article
sources DOAJ
author Kok Victor C
Horng Jorng-Tzong
Lin Hsin-Li
Chen Yu-Ching
Chen Yan-Jun
Cheng Kuang Fu
spellingShingle Kok Victor C
Horng Jorng-Tzong
Lin Hsin-Li
Chen Yu-Ching
Chen Yan-Jun
Cheng Kuang Fu
Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan
BMC Cardiovascular Disorders
author_facet Kok Victor C
Horng Jorng-Tzong
Lin Hsin-Li
Chen Yu-Ching
Chen Yan-Jun
Cheng Kuang Fu
author_sort Kok Victor C
title Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan
title_short Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan
title_full Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan
title_fullStr Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan
title_full_unstemmed Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan
title_sort gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in taiwan
publisher BMC
series BMC Cardiovascular Disorders
issn 1471-2261
publishDate 2012-11-01
description <p>Abstract</p> <p>Background</p> <p>Limited data are available on the risk ratios for fatal cardiovascular disease (CVD) outcome from gout and chronic kidney disease (CKD) in non-diabetic individuals.</p> <p>Methods</p> <p>Nationwide population-based retrospective prospective study with a 5-year follow-up to investigate the association between physician-diagnosed gout and CKD in non-diabetics aged 50 and above who had no pre-existing serious CVD and the subsequent risk of death from CVD. Hazard ratios (HR) of CVD mortality were adjusted for gender, age, smoking- and alcoholism-related diagnoses, hypertension, hyperlipidemia, atrial fibrillation and Charlson’s comorbidity index score.</p> <p>Results</p> <p>A case cohort (n=164,463) having gout and a control cohort (n= 3,694,377) having no gout were formed. The prevalence of gout in this study was 4.26% whereas that of gout plus CKD was 8.17%. Male to female ratio among the individuals with gout was 3.2:1. The relative risk (RR) of subsequent cardiovascular mortality between the case and control cohort was 1.71 (95% confidence interval (CI), 1.66-1.75). The presence of CKD in nondiabetic subjects with no gout (control group) has a RR of CVD mortality at 3.05 (95% CI, 2.94-3.15). The presence of gout has protective effect on subjects with CKD with a RR of 1.84 (95% CI, 1.71-1.98). As compared with individuals with no gout, the adjusted HR (aHR) for CVD mortality among the individuals with gout was 1.10 (95% CI 1.07-1.13). In a Cox model, when compared with subjects having neither gout nor CKD, the aHR in subjects with no gout but with CKD is 1.76 (95% CI, 1.70-1.82); in subjects with gout but without CKD, 1.10 (1.07-1.13); interestingly, the aHR is attenuated in subjects with concomitant gout plus CKD which is 1.38 (1.29-1.48).</p> <p>Conclusions</p> <p>Among non-diabetic individuals aged 50 years or above who had no preceding serious CVD, those with gout were 1.1 times more likely to die from CVD as were individuals without gout. The presence of gout appears to attenuate the risk of subsequent CV mortality in subjects with CKD. Further studies should focus on finding an explanation for the protective effect of gout on CV mortality in patients with CKD.</p>
url http://www.biomedcentral.com/1471-2261/12/108
work_keys_str_mv AT kokvictorc goutandsubsequentincreasedriskofcardiovascularmortalityinnondiabeticsaged50andaboveapopulationbasedcohortstudyintaiwan
AT horngjorngtzong goutandsubsequentincreasedriskofcardiovascularmortalityinnondiabeticsaged50andaboveapopulationbasedcohortstudyintaiwan
AT linhsinli goutandsubsequentincreasedriskofcardiovascularmortalityinnondiabeticsaged50andaboveapopulationbasedcohortstudyintaiwan
AT chenyuching goutandsubsequentincreasedriskofcardiovascularmortalityinnondiabeticsaged50andaboveapopulationbasedcohortstudyintaiwan
AT chenyanjun goutandsubsequentincreasedriskofcardiovascularmortalityinnondiabeticsaged50andaboveapopulationbasedcohortstudyintaiwan
AT chengkuangfu goutandsubsequentincreasedriskofcardiovascularmortalityinnondiabeticsaged50andaboveapopulationbasedcohortstudyintaiwan
_version_ 1724535832026546176